Posted by Michael Wonder on 17 Dec 2016
Albireo’s lead product candidate for orphan paediatric liver disease accepted Into European Medicines Agency’s PRIME program
15 November 2016 - Program designed to speed up evaluation of investigational medicines for diseases with unmet medical need.
Albireo Pharma announced today that its lead product candidate, A4250, has been granted access to the PRIority MEdicines (PRIME) program of the EMA for the treatment of progressive familial intrahepatic cholestasis.
